The Severe Asthma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Severe Asthma Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Severe Asthma Market.
Some of the key takeaways from the Severe Asthma Pipeline Report:
Companies across the globe are diligently working toward developing novel Severe Asthma treatment therapies with a considerable amount of success over the years.
Severe Asthma companies working in the treatment market are Lanier Biotherapeutics, Bio-Thera Solutions, Kinaset Therapeutics, CSPC ZhongQi Pharmaceutical Technology, Oneness Biotech Co., Ltd., Chia Tai Tianqing Pharmaceutical Group, AB Science, GlaxoSmithKline, AstraZeneca, Avillion, Novartis, 4D pharma, Roche, Pieris Pharma, Biosion, Avalo Therapeutics, and others, are developing therapies for the Severe Asthma treatment
Emerging Severe Asthma therapies in the different phases of clinical trials are- LNR 125.38, BAT2606, KN-002, CM326, FB 704A, TQC2731, Masitinib, GSK3511294, PT010, PT027, CSJ117, MRx-4DP0004, RG6173, PRS-060/AZD1402, BSI-045B, AVTX-002, and others are expected to have a significant impact on the Severe Asthma market in the coming years.
In March 2021, A 52-week, randomised, double-blind, placebo-controlled, parallel-group, multi-center study of the effectiveness and safety of GSK3511294 adjuvant therapy in adult and adolescent participants with severe uncontrolled asthma with an eosinophilic phenotype was started by GlaxoSmithKline.
Severe Asthma Overview
The chronic lung disease known as asthma causes the airways to become inflamed and hyperactive. Asthma has a wide range of signs and symptoms that can be brought on by breathing in environmental allergens including pollen, dust, animal dander, mould, or other irritants.
Get a Free Sample PDF Report to know more about Severe Asthma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/severe-asthma-pipeline-insight
Emerging Severe Asthma Drugs Under Different Phases of Clinical Development Include:
LNR 125.38: Lanier Biotherapeutics
BAT2606: Bio-Thera Solutions
KN-002: Kinaset Therapeutics
CM326: CSPC ZhongQi Pharmaceutical Technology
FB 704A: Oneness Biotech Co., Ltd.
TQC2731: Chia Tai Tianqing Pharmaceutical Group
Masitinib: AB Science
GSK3511294: GlaxoSmithKline
PT010: AstraZeneca
PT027: AstraZeneca and Avillion
CSJ117: Novartis
MRx-4DP0004: 4D pharma
RG6173: Roche
PRS-060/AZD1402: Pieris Pharma and AstraZeneca
BSI-045B: Biosion
AVTX-002: Avalo Therapeutics
Severe Asthma Pipeline Therapeutics Assessment
Severe Asthma Assessment by Product Type
Severe Asthma By Stage and Product Type
Severe Asthma Assessment by Route of Administration
Severe Asthma By Stage and Route of Administration
Severe Asthma Assessment by Molecule Type
Severe Asthma by Stage and Molecule Type
DelveInsight’s Severe Asthma Report covers around products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Severe Asthma product details are provided in the report. Download the Severe Asthma pipeline report to learn more about the emerging Severe Asthma therapies
Some of the key companies in the Severe Asthma Therapeutics Market include:
Key companies developing therapies for Severe Asthma are – GSK, AstraZeneca, Avillion, 4D Pharma, Avalo Therapeutics, Biosion, Roche, GenenTech, Boehringer Ingelheim Pharmaceuticals, Amgen, Pfizer, AB Science, Teva Pharmaceuticals, Sanofi, Regeneron Pharmaceuticals, Pieris Pharma, Novartis, Theravance Biopharma, and others.
Severe Asthma Pipeline Analysis:
The Severe Asthma pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Severe Asthma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Severe Asthma Treatment.
Severe Asthma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Severe Asthma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Severe Asthma market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Severe Asthma drugs and therapies
Severe Asthma Pipeline Market Drivers
Increase in the prevalence of Severe Asthma, development of new and innovative treatment options for severe asthma are some of the important factors that are fueling the Severe Asthma Market.
Severe Asthma Pipeline Market Barriers
However, high cost of asthma medications, poor adherence to treatment, limited efficacy of existing treatments and other factors are creating obstacles in the Severe Asthma Market growth.
Scope of Severe Asthma Pipeline Drug Insight
Coverage: Global
Key Severe Asthma Companies: Lanier Biotherapeutics, Bio-Thera Solutions, Kinaset Therapeutics, CSPC ZhongQi Pharmaceutical Technology, Oneness Biotech Co., Ltd., Chia Tai Tianqing Pharmaceutical Group, AB Science, GlaxoSmithKline, AstraZeneca, Avillion, Novartis, 4D pharma, Roche, Pieris Pharma, Biosion, Avalo Therapeutics, and others
Key Severe Asthma Therapies: LNR 125.38, BAT2606, KN-002, CM326, FB 704A, TQC2731, Masitinib, GSK3511294, PT010, PT027, CSJ117, MRx-4DP0004, RG6173, PRS-060/AZD1402, BSI-045B, AVTX-002, and others
Severe Asthma Therapeutic Assessment: Severe Asthma current marketed and Severe Asthma emerging therapies
Severe Asthma Market Dynamics: Severe Asthma market drivers and Severe Asthma market barriers
Request for Sample PDF Report for Severe Asthma Pipeline Assessment and clinical trials
Table of Contents
1. Severe Asthma Report Introduction
2. Severe Asthma Executive Summary
3. Severe Asthma Overview
4. Severe Asthma- Analytical Perspective In-depth Commercial Assessment
5. Severe Asthma Pipeline Therapeutics
6. Severe Asthma Late Stage Products (Phase II/III)
7. Severe Asthma Mid Stage Products (Phase II)
8. Severe Asthma Early Stage Products (Phase I)
9. Severe Asthma Preclinical Stage Products
10. Severe Asthma Therapeutics Assessment
11. Severe Asthma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Severe Asthma Key Companies
14. Severe Asthma Key Products
15. Severe Asthma Unmet Needs
16 . Severe Asthma Market Drivers and Barriers
17. Severe Asthma Future Perspectives and Conclusion
18. Severe Asthma Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services